
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsAC Immune Expands Tau Program Under Lilly AgreementLausanne-based AC Immune amended its 2018 agreement with Eli Lilly to advance new Tau Morphomer small molecules for Alzheimer’s and other neurodegenerative diseases.Fact-Checked
Mergers & AcquisitionsGilead Bolsters ADC Strategy with Tubulis Acquisition Worth Up to $5BGilead Sciences, Inc. agreed to acquisition of Tubulis GmbH, adding clinical-stage ADCs led by TUB-040 in Phase 1b/2 for ovarian cancer and NSCLC, plus next-generation conjugation platforms, in…Fact-Checked
Mergers & AcquisitionsNeurocrine to Acquire Soleno, Strengthening Rare Disease Portfolio with VYKAT XRNeurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion in cash, adding VYKAT XR, a newly approved therapy for hyperphagia in Prader-Willi syndrome, to strengthen its…Fact-Checked
Mergers & AcquisitionsDenali Therapeutics Inc. Regains Full Rights to DNL593 After Takeda Pharmaceutical Company Ends CollaborationImage Courtesy: Denali (Brand fetch) Denali Therapeutics Inc. regains full rights to DNL593 after Takeda Pharmaceutical Company ends collaboration; Phase…Fact-Checked
Mergers & AcquisitionsRegeneron Partners with TriNetX to Leverage 300 Million Patient Records for Research and Digital InnovationRegeneron has partnered with TriNetX to integrate large-scale genomic, proteomic, and real-world clinical data, expanding its EHR-linked database and advancing AI-driven drug discovery.Fact-Checked
Mergers & AcquisitionsLupin Completes VISUfarma Acquisition, Expands European Ophthalmology PortfolioLupin finalizes the acquisition of VISUfarma B.V., adding over 60 eye care brands and strengthening its specialty presence across key European markets.Fact-Checked
Mergers & AcquisitionsZai Lab, Amgen Partner to Advance DLL3 Dual-Targeting Strategy in SCLCZai Lab partners with Amgen Inc. to evaluate a DLL3-targeting combination of zoci and IMDELLTRA® in ES-SCLC, aiming to improve systemic and intracranial responses in this aggressive cancer.Fact-Checked
Mergers & AcquisitionsBioVersys Strikes Ansamycin Antibiotic Deal with Hackensack Meridian HealthBioVersys and Hackensack Meridian Health will jointly develop ansamycin candidates to address non-tuberculous mycobacterial infections, leveraging complementary expertise in antimicrobial research.Fact-Checked
Mergers & AcquisitionsAxsome-Takeda Deal Brings Balipodect into Late-Stage CNS DevelopmentAxsome Therapeutics strengthens its CNS pipeline by acquiring balipodect, a novel PDE10A inhibitor from Takeda Pharmaceutical Company, with planned Phase 3 development in Schizophrenia.Fact-Checked
Mergers & AcquisitionsBiogen’s $5.6B Apellis Deal Boosts Immunology and Rare Disease PortfolioBiogen’s $5.6 billion acquisition of Apellis brings two marketed complement therapies, EMPAVELI and SYFOVRE, boosting near-term revenue while expanding its footprint in immunology, nephrology, ophthalmology, and rare immune-driven…Fact-Checked
Mergers & AcquisitionsGalapagos – Gilead Finalize Ouro-Linked Deal to Advance GamgertamigGalapagos and Gilead have finalized a framework agreement linked to Gilead’s acquisition of Ouro Medicines, bringing gamgertamig into a structured co-development pathway for autoimmune diseases.Fact-Checked
Mergers & AcquisitionsLilly to Acquire Centessa in $6.3B Deal, Expands Orexin Pipeline for Sleep DisordersLilly moves to acquire Centessa following strong Phase 2 data for cleminorexton, aiming to accelerate development of orexin-based therapies for sleep-wake disorders.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.